These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 17346697

  • 1. A quantitative method for measuring the antitumor potency of recombinant human endostatin in vivo.
    Xu YF, Zhu LP, Hu B, Rong ZG, Zhu HW, Xu JM, Wu ZW, Wang JJ, Xu GX.
    Eur J Pharmacol; 2007 Jun 14; 564(1-3):1-6. PubMed ID: 17346697
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors.
    Zhu LP, Xing J, Wang QX, Kou L, Li C, Hu B, Wu ZW, Wang JJ, Xu GX.
    Eur J Pharmacol; 2009 Sep 01; 617(1-3):23-7. PubMed ID: 19615993
    [Abstract] [Full Text] [Related]

  • 3. [Studies on antitumor activity of rhEndostatin].
    Li HY, Li Y, Liu ZH, Wu HJ, Chen FH, Chen XG.
    Yao Xue Xue Bao; 2002 Oct 01; 37(10):763-6. PubMed ID: 12567857
    [Abstract] [Full Text] [Related]

  • 4. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
    Plum SM, Hanson AD, Volker KM, Vu HA, Sim BK, Fogler WE, Fortier AH.
    Clin Cancer Res; 2003 Oct 01; 9(12):4619-26. PubMed ID: 14555538
    [Abstract] [Full Text] [Related]

  • 5. The methods for determining the purity and in vitro or in vivo activity of recombinant human endostatin.
    Zhang HY, Han QW, Xu YF, Fan YR, Dai QM, Xu JM, Zhu HW, Rong ZG, Wang JJ, Xu GX.
    Cancer Biol Ther; 2005 Feb 01; 4(2):207-12. PubMed ID: 15753663
    [Abstract] [Full Text] [Related]

  • 6. Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.
    Ren Z, Wang Y, Jiang W, Dai W, Jiang Y.
    PLoS One; 2014 Feb 01; 9(9):e107823. PubMed ID: 25229620
    [Abstract] [Full Text] [Related]

  • 7. Expression of soluble, biologically active recombinant human endostatin in Escherichia coli.
    Xu HM, Zhang GY, Ji XD, Cao L, Shu L, Hua ZC.
    Protein Expr Purif; 2005 Jun 01; 41(2):252-8. PubMed ID: 15866710
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
    Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS.
    J Clin Oncol; 2006 Aug 01; 24(22):3555-61. PubMed ID: 16877721
    [Abstract] [Full Text] [Related]

  • 9. Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin.
    Hu B, Zhu HW, Zhu LP, Li C, Rong ZG, Xu JM, Wu ZW, Wang JJ, Xu GX.
    Acta Pharmacol Sin; 2008 Nov 01; 29(11):1357-69. PubMed ID: 18954531
    [Abstract] [Full Text] [Related]

  • 10. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 01; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve.
    Celik I, Sürücü O, Dietz C, Heymach JV, Force J, Höschele I, Becker CM, Folkman J, Kisker O.
    Cancer Res; 2005 Dec 01; 65(23):11044-50. PubMed ID: 16322254
    [Abstract] [Full Text] [Related]

  • 12. Effects of recombinant human endostatin on a human neuroblastoma xenograft.
    Kuroiwa M, Ikeda H, Hongo T, Tsuchida Y, Hirato J, Kaneko Y, Suzuki N, Obana K, Makino SI.
    Int J Mol Med; 2001 Oct 01; 8(4):391-6. PubMed ID: 11562777
    [Abstract] [Full Text] [Related]

  • 13. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma.
    Kuroiwa M, Takeuchi T, Lee JH, Yoshizawa J, Hirato J, Kaneko S, Choi SH, Suzuki N, Ikeda H, Tsuchida Y.
    J Pediatr Surg; 2003 Oct 01; 38(10):1499-505. PubMed ID: 14577075
    [Abstract] [Full Text] [Related]

  • 14. Endostatin therapy reveals a U-shaped curve for antitumor activity.
    Tjin Tham Sjin RM, Naspinski J, Birsner AE, Li C, Chan R, Lo KM, Gillies S, Zurakowski D, Folkman J, Samulski J, Javaherian K.
    Cancer Gene Ther; 2006 Jun 01; 13(6):619-27. PubMed ID: 16456550
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of fibroblast-like synoviocyte apoptosis induced by recombinant human endostatin in rats with adjuvant arthritis.
    Huang XY, Chen FH, Li J, Xia LJ, Liu YJ, Zhang XM, Yuan FL.
    Anat Rec (Hoboken); 2008 Aug 01; 291(8):1029-37. PubMed ID: 18509875
    [Abstract] [Full Text] [Related]

  • 16. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin.
    Nie Y, Zhang X, Wang X, Chen J.
    Bioconjug Chem; 2006 Aug 01; 17(4):995-9. PubMed ID: 16848407
    [Abstract] [Full Text] [Related]

  • 17. [Experimental study on antitumor effect of extracts from Cestrum nocturnum in vivo].
    Zhong ZG, Zhao SY, Lv JY, Li P.
    Zhong Yao Cai; 2008 Nov 01; 31(11):1709-12. PubMed ID: 19260288
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunomodulatory and antitumor activity of triterpenoid fractions from the rhizomes of Astilbe chinensis.
    Tu J, Sun HX, Ye YP.
    J Ethnopharmacol; 2008 Sep 26; 119(2):266-71. PubMed ID: 18692123
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.